The anti-tumor effects of lung cancer-targeting long-circulating paclitaxel-containing liposomes

Tumor

Volumn 31, Issue 3, 2011, Pages 203-209

  Zhou, Wei ^a   Zhou, Cai Cun ^a   Meng, Shu Yan ^a   Su, Bo ^a   Song, Yin ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Liposomes; Lung neoplasms; Nanotechnology; Paclitaxel; Pharmacokinetics; Tissue distribution; Toxicity tests

Indexed keywords

AMINOCAPROIC ACID; ARGININE; ASPARTIC ACID; GLYCINE; LIPOSOME; PACLITAXEL; PALMITIC ACID; STERICALLY STABILIZED LIPOSOME PACLITAXEL; TARGETING STERICALLY STABILIZED LIPOSOME PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CIRCULATION TIME; CONTROLLED STUDY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SAFETY; DRUG TARGETING; ENCAPSULATION; FILM; GROWTH RETARDATION; IN VIVO STUDY; LUNG CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PARTICLE SIZE; SOLID PHASE SYNTHESIS; TISSUE DISTRIBUTION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR GROWTH; ULTRASOUND;

EID: 79953213360     PISSN: 10007431     EISSN: None     Source Type: Journal    
DOI: 10.3781/j.issn.1000-7431.2011.03.004     Document Type: Article

References (16)

1. WEISS R B, DONEHOWER R C, WIERNIK P H, et al. Hypersensitivity reactions from taxol [J]. J Clin Oncol, 1990, 8(7): 1263-1268.
2. SPARREBOOM A, VAN TELLINGEN O, NOOIJEN W J, et al. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL [J]. Cancer Res, 1996, 56(9): 2112-2115.
3. PASQUALINI R, ARAP W, MCDONALD D M. Probing the structural and molecular diversity of tumor vasculature [J]. Trends Mol Med, 2002, 8(12): 563-571.
4. MAKRILIA N, LAPPA T, XYLA V, et al. The role of angiogenesis in solid tumor: an overview [J]. Eur J Intern Med, 2009, 20(7): 663-671.
5. SMOLARCZYK R, CICHON T, GRAJA K, et al. Antitumor effect of RGD-4C-GG-D (KLAKLAK)2 peptide in mouse B16(F10) melanoma model [J]. Acta Biochim Pol, 2006, 53(4): 801-805.
6. YANG T, CHOI M K, CUI F D, et al. Antitumor effect of paclitaxel - loaded PEGylated immunoliposomes against human breast cancer cells [J]. Pharm Res, 2007, 24(12): 2402-2411.
7. SHARMA A, STRAUBINGER R M. Novel taxol formulations: preparation and characterization of taxol-containing liposomes [J]. Pharm Res, 1994, 11(6): 889-896.
8. YANG T, CUI F D, CHOI M K, et al. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation [J]. Int J Pharm, 2007, 338(1-2): 317-326.
9. KOO O M, RUBINSTEIN I, ONYUKSEL H. Role of nanotechnology in targeted drug delivery and imaging: a concise review [J]. Nanomedicine, 2005, 1(3): 193-212.
10. SRINIVASAN R, MARCHANT R E, GUPTA A S. In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes [J]. J Biomed Mater Res A, 2010, 93(3): 1004-1015.
11. RAMAKRISHNA N, GEORAGE C W, CHRISTOPHER B P, et al. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation [J]. AAPS PharmSciTech, 2006, 7(2): E32.
12. GARG A, TISDALE A W, HAIDARI E, et al. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide [J]. Int J Pharm, 2009, 366(1-2): 201-210.
13. BYRNE J D, BETANCOURT T, BRANNON-PEPPAS L. Active targeting schemes for nanoparticle systems in cancer therapeutics [J]. Adv Drug Deliv Rev, 2008, 60(15): 1615-1626.